Analysts Offer Predictions for Delcath Systems Q3 Earnings

Delcath Systems, Inc. (NASDAQ:DCTH) – Stock analysts at HC Wainwright upped their Q3 2026 earnings per share (EPS) estimates for Delcath Systems in a report released on Friday, August 7th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.10) per share for the quarter, up from their prior forecast of ($0.29). HC Wainwright currently has a “Buy” rating and a $32.00 target price on the stock. The consensus estimate for Delcath Systems’ current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Delcath Systems’ Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.17) EPS, FY2027 earnings at $0.12 EPS, FY2028 earnings at $0.56 EPS, FY2029 earnings at $0.97 EPS and FY2030 earnings at $1.46 EPS.

Delcath Systems (NASDAQ:DCTH) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.16. The business had revenue of $29.13 million for the quarter, compared to analyst estimates of $26.25 million. Delcath Systems had a return on equity of 0.46% and a net margin of 0.56%.

Several other equities research analysts have also recently issued reports on DCTH. Zacks Research raised shares of Delcath Systems from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 7th. Weiss Ratings reissued a “sell (d+)” rating on shares of Delcath Systems in a research note on Friday. BTIG Research raised their target price on shares of Delcath Systems from $17.00 to $21.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Finally, Wall Street Zen raised shares of Delcath Systems from a “hold” rating to a “buy” rating in a research note on Saturday. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $23.17.

Delcath Systems Trading Up 10.3%

Shares of DCTH stock opened at $16.67 on Tuesday. The firm has a 50-day moving average price of $12.48 and a 200 day moving average price of $10.92. Delcath Systems has a twelve month low of $8.12 and a twelve month high of $16.69. The company has a market capitalization of $578.45 million, a price-to-earnings ratio of 1,668.67 and a beta of 0.52.

Hedge Funds Weigh In On Delcath Systems

A number of hedge funds have recently made changes to their positions in the stock. Rosalind Advisors Inc. boosted its holdings in shares of Delcath Systems by 13.8% in the 2nd quarter. Rosalind Advisors Inc. now owns 3,300,389 shares of the company’s stock valued at $44,885,000 after purchasing an additional 400,000 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Delcath Systems by 2.9% during the 3rd quarter. Vanguard Group Inc. now owns 1,657,428 shares of the company’s stock worth $17,817,000 after buying an additional 46,693 shares during the last quarter. Nantahala Capital Management LLC acquired a new stake in shares of Delcath Systems during the 3rd quarter worth $7,164,000. Goldman Sachs Group Inc. raised its position in shares of Delcath Systems by 116.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 587,678 shares of the company’s stock worth $5,936,000 after buying an additional 315,583 shares during the period. Finally, ExodusPoint Capital Management LP raised its position in shares of Delcath Systems by 30.9% in the 4th quarter. ExodusPoint Capital Management LP now owns 496,705 shares of the company’s stock worth $5,017,000 after buying an additional 117,122 shares during the period. Institutional investors and hedge funds own 61.12% of the company’s stock.

Delcath Systems Company Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.